OEE & Downtime in Pharmaceutical Manufacturing
Key takeaways
- Pharma OEE often runs 40 to 65 percent because compliance work eats availability others never see.
- The big losses: cleaning and changeover validation, documentation, and serialization stops.
- Quality is non-negotiable, so a defect or deviation is unusually expensive.
- Accurate, traceable stop data supports audit-readiness as well as improvement.
Pharmaceutical manufacturing optimises for compliance and patient safety first, throughput second, and rightly so. The result is an OEE profile unlike any other sector: large, necessary availability losses around cleaning, validation and documentation, plus packaging lines that share every micro-stop problem of high-speed filling.
What's a good OEE in pharma?
Many pharmaceutical lines sit at 40 to 65 percent OEE, below the 85 percent world-class reference. The gap is not all waste: validated cleaning, changeover and in-process checks are required. The opportunity is to shrink the avoidable part (long changeovers, unlogged micro-stops) without touching what compliance requires. Calculate your OEE.
The biggest losses in pharma
| Loss | Why it's big in pharma | OEE factor |
|---|---|---|
| Cleaning & changeover validation | Validated cleaning and verification between products and batches is long and mandatory | Availability |
| Documentation & in-process checks | Batch records, line clearance and in-process testing pause production | Availability |
| Serialization & aggregation stops | Track-and-trace coding, vision checks and rejects on packaging lines | Performance / Quality |
| Filler / blister / capper micro-stops | High-speed packaging shares the hidden factory problem | Performance |
| Quality holds & reduced yield | Deviations and rejects are costly and trigger investigation | Quality |
Separate the validated, required downtime from the recoverable micro-stops and changeover drift.
What downtime costs in pharma
High product value, batch-based production and strict release testing mean a stoppage can put an entire batch at risk, not just a few minutes of output. Add the cost of investigations and the picture is clear: even modest, recoverable losses are worth chasing. Estimate your downtime cost.
How leading pharma plants improve
- Separate required from avoidable downtime so improvement targets the recoverable part only.
- Attack changeover and cleaning time with SMED-style standard work, within validation.
- Capture every stop accurately for both improvement and a traceable record.
The partner we recommend, , reads OEE and stops straight from the line and shows the true cause of micro-stops on video, giving an accurate, time-stamped record that supports audit-readiness and targets the recoverable losses. It is EU-built with EU data residency and holds ISO 27001 / 20000-1 / 9001. Fabrico is a partner we recommend; the tools here are free regardless.
Should validated cleaning count against OEE?
It is required downtime during planned production time, so it does reduce OEE. The point is not to cut what compliance requires, but to reduce the avoidable losses around it and to keep cleaning efficient.
How does this help with audits?
Automatic, time-stamped capture of every stop and its cause gives a complete, accurate line history, which supports audit-readiness. It does not by itself make a site compliant; it provides better evidence and control.
Where is the fastest gain?
Usually the unlogged micro-stops on packaging and serialization lines, plus tightening changeover time within the validated procedure.
Common equipment to troubleshoot: Tablet presses · Blister packers · Autoclaves · Labellers · Filling machines · full directory